Broad Institute's gene-editing technologies—CRISPR-Cas9, base editing, and prime editing—are being tested in more than 25 clinical trials to treat or cure leukemias, rare genetic diseases, …

Broad Clinical Labs (BCL), a CLIA-licensed and CAP-accredited wholly owned subsidiary of the Broad Institute, offers a range of research and clinical services that empower multi-omic data …

Broad Institute's gene-editing technologies—CRISPR-Cas9, base editing, and prime editing—are being tested in more than 25 clinical trials to treat or cure leukemias, rare genetic diseases, …

Broad Institute scientists are using AI to design new antibiotics and other drugs, predict drug toxicity, and pinpoint genes, molecules, and cells that might be causing disease.

Sep 11, 2023 · Broad Institute scientists are using AI to design new antibiotics and other drugs, predict drug toxicity, and pinpoint genes, molecules, and cells that might be causing disease.

Broad Institute scientists are using AI to design new antibiotics and other drugs, predict drug toxicity, and pinpoint genes, molecules, and cells that might be causing disease.

The Broad Institute is an independent, non-profit research organization that aims to discover the root causes of all common and rare diseases, and to use this insight to help develop safe and …

Broad Institute's gene-editing technologies—CRISPR-Cas9, base editing, and prime editing—are being tested in more than 25 clinical trials to treat or cure leukemias, rare genetic diseases, …

The Broad faculty consists of Institute Members and Associate Members. Institute Members are deeply engaged in the intellectual life of Broad and are responsible for setting its scientific …

Based primarily in Kendall Square in Cambridge, Massachusetts, the Broad Institute was founded in 2004 to fulfill the promise of genomic medicine — three years after completion of the Human …